Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – – This is the first time that any antiviral used in ...
--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase III CENTERSTONE study of Xofluza ® (baloxavir ...
The study met its primary endpoint, demonstrating that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household ...
Some results have been hidden because they may be inaccessible to you